Dear Kate,

Prostate Cancer UK was pleased to learn that NICE are proposing to recommend the use of degarelix as an option for hormone-dependent prostate cancer, only in people with spinal metastases who are at risk of impending spinal cord compression. We believe that the Committee has taken account of the criteria as set out in the Appraisal consultation document.

We hope this decision is confirmed at the Committee meeting on 11th February 2014. We would then urge the Final Appraisal Document be published as soon as possible.

Best wishes,

[redacted]

[redacted]

Prostate Cancer UK
[redacted]